Hims & Hers Health, Inc. (NYSE:HIMS) Receives $14.85 Consensus PT from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $15.07.

A number of equities analysts have recently commented on HIMS shares. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective on the stock. SVB Leerink initiated coverage on Hims & Hers Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $10.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Finally, Piper Sandler lifted their target price on Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $12.36 on Friday. The business’s 50-day simple moving average is $14.04 and its 200-day simple moving average is $10.35. The firm has a market capitalization of $2.65 billion, a PE ratio of -112.27 and a beta of 0.97. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) earnings per share. Research analysts forecast that Hims & Hers Health will post 0.11 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 4,080 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the transaction, the insider now directly owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 736,191 shares of company stock valued at $9,733,700. 31.63% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HIMS. Vanguard Group Inc. raised its position in Hims & Hers Health by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after purchasing an additional 46,541 shares during the last quarter. Forerunner Ventures Management LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $86,836,000. Dimensional Fund Advisors LP raised its position in shares of Hims & Hers Health by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after acquiring an additional 193,507 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Hims & Hers Health by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock valued at $11,523,000 after acquiring an additional 22,009 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Hims & Hers Health by 38.6% during the 3rd quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock valued at $6,494,000 after acquiring an additional 287,552 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.